Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myotonic dystrophy: approach to therapy.

Charles A Thornton1, Eric Wang2, Ellie M Carrell1

  • 1Department of Neurology, University of Rochester, Rochester 14642, NY, United States.

Current Opinion in Genetics & Development
|April 5, 2017
PubMed
Summary

Myotonic dystrophy (DM) therapies target toxic RNA repeats. Recent research reveals novel mechanisms and therapeutic strategies for DM, offering new hope for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elimination of myotonia improves myopathy in a muscleblind-like knockout model of myotonic dystrophy.

Nature communications·2026
Same author

The AAHKS Clinical Research Award: Maximizing Bearing Size Markedly Reduces Dislocations in Primary Total Hip Arthroplasty.

The Journal of arthroplasty·2026
Same author

Endoscopic resection of knosp grade 0-2 growth hormone-secreting pituitary adenomas with routine medial cavernous sinus wall excision.

Acta neurochirurgica·2026
Same author

Design, Preclinical Evaluation, and Clinical Translation of [68Ga]Ga/[177Lu]Lu-JH120061, A Novel Radiopharmaceutical Targeting CXCR4.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Estimating temporal treatment-effect patterns of radiotherapy and chemotherapy in lower-grade gliomas using causal machine learning.

Scientific reports·2026
Same author

Differential epigenetic regulation of glucose-induced alteration of miR-9 in retinal and cardiac endothelial cells.

PloS one·2026

Area of Science:

  • Genetics and Molecular Biology
  • Neurology
  • Pharmacology

Background:

  • Myotonic dystrophy (DM) is a genetic disorder impacting multiple organs, caused by repeat expansions in DMPK (DM1) or CNBP (DM2).
  • DM mutations result in the expression of toxic, dominant-acting RNAs that drive disease pathology.
  • Understanding RNA toxicity mechanisms is crucial for developing effective DM treatments.

Purpose of the Study:

  • To review recent advancements in understanding and alleviating RNA toxicity in myotonic dystrophy.
  • To highlight novel therapeutic targets and strategies for DM based on RNA toxicity mechanisms.
  • To summarize preclinical data supporting therapeutic interventions for DM.

Main Methods:

  • Review of current scientific literature on myotonic dystrophy pathogenesis and RNA toxicity.

Related Experiment Videos

  • Analysis of studies investigating novel therapeutic approaches targeting RNA in DM models.
  • Synthesis of preclinical data on the efficacy of various therapeutic interventions.

    • Main Results:

    • RNA toxicity is a key driver of myotonic dystrophy, with distinct repeat expansions in DM1 and DM2.
    • Novel mechanisms of RNA toxicity have been elucidated, revealing new therapeutic targets.
    • Preclinical studies demonstrate that RNA toxicity is amenable to therapeutic intervention at multiple levels.

    Conclusions:

    • Therapeutic strategies targeting toxic RNA offer promising avenues for treating myotonic dystrophy.
    • Further research into RNA-dominant mechanisms can lead to more effective DM therapies.
    • Developing interventions that alleviate RNA toxicity is essential for managing DM progression.